Pulnovo Medical

Pulnovo Medical is a clinical-stage medical technology company specializing in the development of first-in-class interventional therapies for cardiovascular and pulmonary diseases. The company’s core innovation is the Pulmonary Artery Denervation (PADN) system, a minimally invasive technology that utilizes radiofrequency ablation to treat pulmonary hypertension and heart failure. By targeting sympathetic nerves in the pulmonary artery, the system aims to reduce arterial pressure and improve long-term clinical outcomes for patients who have limited options with traditional drug therapies.

The company operates within the global medical device market, serving healthcare providers and specialized cardiovascular centers. Its business model is centered on the rigorous research, clinical validation, and manufacturing of its proprietary catheter and generator systems. Currently, Pulnovo Medical generates value through the commercialization of its NMPA-approved products in China and Southeast Asia, while simultaneously pursuing high-stakes clinical trials to secure regulatory clearance in the United States and Europe.

Key features of the PADN system include its multi-pole synchronous ablation technology and a ring-shaped catheter design that ensures precise energy delivery. The company has secured several prestigious regulatory milestones, including the FDA's Breakthrough Device Designation and multiple Investigational Device Exemption (IDE) approvals. With over 1,500 clinical applications globally, Pulnovo Medical leverages deep clinical data and a robust intellectual property portfolio to maintain its leadership in the pulmonary intervention space.

Keywords: medical devices, pulmonary hypertension, heart failure, radiofrequency ablation, interventional cardiology, PADN technology, clinical trials, cardiovascular health, minimally invasive surgery, medtech.